HPA045153
抗-PRAME 兔抗
Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
别名:
抗-Ct130, 抗-Mape, 黑色素瘤中的抗-优先表达抗原
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
product line
Prestige Antibodies® Powered by Atlas Antibodies
form
buffered aqueous glycerol solution
species reactivity
human
enhanced validation
orthogonal RNAseq
recombinant expression
Learn more about Antibody Enhanced Validation
technique(s)
immunoblotting: 0.04-0.4 μg/mL, immunohistochemistry: 1:200-1:500
immunogen sequence
LLLSHIHASSYISPEKEEQYIAQFTSQFLSLQCLQALYVDSLFFLRGRLDQLLRHVMNPLETLSITNCRLSEGDVMHLSQSPSVSQLSVLSLSGVMLTDVSPEPLQALLERASATLQDLVFDECGI
UniProt accession no.
application(s)
research pathology
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... PRAME(23532)
General description
PRAME基因（黑色素瘤中优先表达的抗原）定位于人类染色体22q11。编码的蛋白属于癌症D睾丸抗原家族。它是一种肿瘤相关抗原。PRAME在正常组织中表达非常低或没有表达。
PRAME蛋白可与以下成分相互作用：
PRAME蛋白可与以下成分相互作用：
- CUL2（抗-CUL2 HPA024578）
- TCEB1（抗-TCEB1 HPA078113）
- TCEB2（抗-TCEB2 SAB1409726）
Immunogen
黑色素瘤中优先表达的抗原重组蛋白表位标签（PrEST）
Application
由Atlas Antibodies提供技术支持的所有Prestige Antibodies®抗体均由人类蛋白质图集（HPA）项目开发和验证。每种抗体都通过针对数百种正常和疾病组织的免疫组织化学进行测试。通过单击图像库链接，可以在人类蛋白质图谱（HPA）站点上查看这些图像。我们还提供Prestige Antibodies® 抗体的实验方案和其他有用信息。
兔抗PRAME抗体可用于蛋白质印迹、免疫组化和免疫荧光。
兔抗PRAME抗体可用于蛋白质印迹、免疫组化和免疫荧光。
Biochem/physiol Actions
PRAME（黑色素瘤中优先表达的抗原）在恶性细胞中过表达，包括原发性和转移性黑色素瘤，急性和慢性白血病，霍奇金氏淋巴瘤，乳腺癌和头颈部鳞状细胞癌。在AML（急性髓样白血病）中，PRAME的高水平与较低的复发性率和高的无疾病生存期机会相关。PRAME在视黄醇途径中也起作用。它调节全反式视黄醇（维生素A）及其活性代谢物（称为类维生素A）的代谢。它是视黄酸受体信号传导的阻遏物。
Features and Benefits
Prestige Antibodies®是经过高度表征和广泛验证的抗体，同时还有一个优点是其每个靶标的所有可用表征数据都可以通过位于此页面顶部产品名称下方的人类蛋白质图谱门户进行访问。Prestige Antibodies®对其他蛋白质的独特性和低交叉反应性是通过严密的抗原区域选择、亲和纯化和严格的选择来实现的。每种Prestige 抗体都有相应的Prestige 抗原对照品，可在链接部分找到。
每种Prestige 抗体的检测方法如下：
每种Prestige 抗体的检测方法如下：
- 44种正常人体组织和20种最常见癌症组织的IHC组织阵列。
- 364个人重组蛋白片段的蛋白阵列。
Physical form
磷酸盐缓冲盐水溶液，pH 7.2，含有 40% 甘油和 0.02% 叠氮化钠
Other Notes
对应抗原APREST70289
Legal Information
Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
低风险生物材料
常规特殊物品
此项目有
Elevated PRAME expression: what does this mean for treatment of head and neck squamous cell carcinoma?
Szczepanski MJ and Whiteside TL
Biomarkers in Medicine, 7, 575-578 (2013)
Y Xu et al.
European review for medical and pharmacological sciences, 20(6), 1057-1063 (2016-04-07)
PRAME (Preferentially Expressed Antigen in Melanoma) is a tumor-associated antigen recognized by immunocytes, and it induces cytotoxic T cell-mediated responses in melanoma. PRAME is expressed in a wide variety of tumors, but in contrast with most other tumor-associated antigens, it
Daniel Nettersheim et al.
British journal of cancer, 115(4), 454-464 (2016-07-22)
Cancer/testis-antigens (CTAs) are specifically expressed in human malignancies and testis tissue, but their molecular functions are poorly understood. CTAs serve as regulators of gene expression, cell cycle and spermatogenesis, as well as targets for immune-based therapies. The CTA PRAME is
Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene.
Gunn SR, et al.
Leukemia Research, 33, 1276-1281 (2009)
Yohei Taniguchi et al.
Scientific reports, 10(1), 12286-12286 (2020-07-25)
Thymic squamous cell carcinoma (TSQCC), accounting for 70-80% of thymic carcinoma cases, is distinct from thymoma. However, differential diagnosis for type B3 thymoma is sometimes challenging, even with established markers for TSQCC, including KIT and CD5, which are expressed in ~ 80%
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持